ERS Genomics

ERS is the world leader in licensing CRISPR/Cas9 technology for a wide variety of applications.
Our founder, Dr. Emmanuelle Charpentier (the ‘E’in ERS) won the Nobel Prize for the discovery of CRISPR/Cas9 in 2020. 

Without question, CRISPR/Cas9 has transformed the field of gene editing. 
At ERS Genomics, our purpose is to extend global access to this technology and expand the boundaries of CRISPR potential.


BIO International is the perfect time to start or continue a conversation about your CRISPR license. We are excited to connect with companies who can benefit from our game-changing technology. A meeting or a call with us is worthwhile for you if:

You are interested in possible use of CRISPR/Cas9 for internal research programs:
– Are you using modified cells or animals from an academic source?
– Are you generating in-house reagents?


You are interested in use of genetically modified cells in manufacturing. Including… 
– mAbs
– Gene or cell therapy
– Vectors
– Industrial enyzmes or intermediates


You provide any services that use CRISPR/Cas9 or cells or animals modified by the technology. Including…
– High-throughput screening 
– Target identification, Target validation
– Cell line development
– Disease specific cell models
– Animal models of disease


You have an interest in animal health applications. Including… 
Disease resistance, Vaccines Trait improvements

Drop by our Booth, 2549, to connect or schedule a BIO Partnering meeting.


Schedule time with ERS

Jon Kratochvil


‘If you’re using or plan to use CRISPR/Cas9
technology, you need a License
from ERS Genomics.’

Connect with us @ Bio Boston in June.
Getting a license is easy, fast & flexible.

Jon Kratochvil, Vice President,  ERS Genonics.


Intellectual Property

Knowledge Centre

Contact US

Read More Of Our Articles

Explore more news on CRISPR/Cas9 and how it can provide a leading edge in the highly competitive biotech sector.

ERS Genomics and IRBM sign CRISPR/Cas9 license agreement

License agreement provides IRBM access to CRISPR gene editing technology to be applied across its drug discovery services offering Dublin, Ireland, and Rome, Italy, 20 May 2024: ERS Genomics Limited (‘ERS’), the CRISPR licensing Company, and IRBM, a leader in the field of drug discovery, today announced a non-exclusive CRISPR/Cas9.

Read Full Article

ERS Genomics appoints John E Milad as Chief Executive Officer

Dublin, Ireland, 13 May 2024: ERS Genomics Limited (‘ERS’), the CRISPR licensing company, today announced the appointment of John E Milad as CEO, with immediate effect. John brings over 25 years of experience as an executive leader, venture capitalist, and investment banker focused on the life sciences and medical technology.

Read Full Article

Update: Key Charpentier/Doudna CRISPR patent upheld by China National Intellectual Property Administration

Patent Upheld by China National Intellectual Property Administration Dublin, Ireland, 26 March 2024: ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, today announced its patent CN201380038920.6 was upheld by the China National Intellectual Property Administration (CNIPA) in.

Read Full Article